Literature DB >> 20162570

Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma.

Jörg Ellinger1, Philip Kahl, Claudia Mertens, Sebastian Rogenhofer, Stefan Hauser, Wolfgang Hartmann, Patrick J Bastian, Reinhard Büttner, Stefan C Müller, Alexander von Ruecker.   

Abstract

Epigenetic alterations play an important role in carcinogenesis. Recent studies suggested that global histone modifications are predictors of cancer recurrence in various tumor entities. Our study was performed to evaluate histone H3 lysine 4 mono-methyl (H3K4me1), -di-methyl (H3K4me2) and -trimethyl (H3K4me3) patterns in renal cell carcinoma (RCC) using a tissue microarray with 193 RCC (including 142 clear cell, 31 papillary, 10 chromophobe and 10 sarcomatoid RCC) and 10 oncocytoma specimens: H3K4me3 staining was more intense in papillary RCC, whereas H3K4me1 and H3K4me2 were similar in the diverse RCC subtypes. H3K4me2 and H3K4me3 levels were increased in oncocytoma. H3K4me1-3 levels were inversely correlated with Fuhrman grading, pT stage, lymph node involvement and distant metastasis. Progression-free survival and cancer-specific survival were shorter in patients with low levels of H3K4me1-3 in the univariate analysis, but we did not observe a significant correlation of a single modification in a multivariate model, which also included the established prognostic parameters TNM-stage and Fuhrman grade. In comparison, the H3K4me score, which combined staining levels of the H3K4 modifications, was an independent predictor of RCC progression-free survival. Our study on H3K4 methylation supports the concept of global histone modifications as potential cancer prognosis markers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20162570     DOI: 10.1002/ijc.25250

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  46 in total

Review 1.  Epigenetics of kidney cancer and bladder cancer.

Authors:  Amanda M Hoffman; Paul Cairns
Journal:  Epigenomics       Date:  2011-02       Impact factor: 4.778

Review 2.  Global histone post-translational modifications and cancer: Biomarkers for diagnosis, prognosis and treatment?

Authors:  Shafqat Ali Khan; Divya Reddy; Sanjay Gupta
Journal:  World J Biol Chem       Date:  2015-11-26

3.  Histone modifications and cancer: biomarkers of prognosis?

Authors:  Yana Chervona; Max Costa
Journal:  Am J Cancer Res       Date:  2012-08-20       Impact factor: 6.166

Review 4.  Chromatin dynamics: H3K4 methylation and H3 variant replacement during development and in cancer.

Authors:  Moonmoon Deb; Swayamsiddha Kar; Dipta Sengupta; Arunima Shilpi; Sabnam Parbin; Sandip K Rath; Vedang A Londhe; Samir Kumar Patra
Journal:  Cell Mol Life Sci       Date:  2014-03-28       Impact factor: 9.261

5.  Tyrosine kinase expression profile in clear cell renal cell carcinoma.

Authors:  Turang E Behbahani; Claudia Thierse; Claudia Baumann; Daniel Holl; Patrick J Bastian; Alexander von Ruecker; Stefan C Müller; Jörg Ellinger; Stefan Hauser
Journal:  World J Urol       Date:  2011-10-04       Impact factor: 4.226

Review 6.  Genetic and epigenetic alterations during renal carcinogenesis.

Authors:  Eri Arai; Yae Kanai
Journal:  Int J Clin Exp Pathol       Date:  2010-12-13

7.  Kdm4b histone demethylase is a DNA damage response protein and confers a survival advantage following γ-irradiation.

Authors:  Leah C Young; Darin W McDonald; Michael J Hendzel
Journal:  J Biol Chem       Date:  2013-06-06       Impact factor: 5.157

8.  The expression and significance of histone lysine methylation in endometrial cancer.

Authors:  Qing Li; Nan Jia; Xiang Tao; Keqin Hua; Weiwei Feng
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

Review 9.  Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma.

Authors:  Swathi Ramakrishnan; Roberto Pili
Journal:  Cancer J       Date:  2013 Jul-Aug       Impact factor: 3.360

Review 10.  DNA Methylation and Urological Cancer, a Step Towards Personalized Medicine: Current and Future Prospects.

Authors:  Javier C Angulo; Jose I López; Santiago Ropero
Journal:  Mol Diagn Ther       Date:  2016-12       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.